Largest ever Parkinson’s research trial is starting now
Date
Research news
Date
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
Date
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Date
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Date
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Date
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Date
Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Date
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
Date
GDNF clinical trial results in 2019 revealed signs that GDNF may make it possible to repair the cells damaged in people with Parkinson’s. We take a look at where we are 1 year later.
Date
A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Date
New research suggests that a bacteria which boosts digestive health can slow – and even reverse – the build-up of a protein associated with Parkinson’s.